Myeloperoxidase: The good, the bad, and the ugly

Current Immunology Reviews

Volumn 6, Issue 2, 2010, Pages 123-129

  Lefkowitz, Doris L ^a   Moné, James ^b   Lefkowitz, Stanley S ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b MILLERSVILLE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease (AD); Immunopathology; Multiple sclerosis (MS); Myeloperoxidase (MPO); Parkinson's disease (PD); Rheumatoid arthritis (RA); Vasculitis

Indexed keywords

MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; REACTIVE OXYGEN METABOLITE;

ARTICLE; ASTHMA; ATHEROSCLEROSIS; CELL KILLING; CYTOKINE PRODUCTION; DEGENERATIVE DISEASE; ENDOTHELIAL DYSFUNCTION; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; PRIORITY JOURNAL; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS;

EID: 77952536745     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339510791111691     Document Type: Article

References (81)

1. Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol 2005; 77(5): 598-625.
2. Suzuki K, Muso E, Nauseef WM. Contribution of peroxidases in host-defense, diseases and cellular functions. Jpn J Infect Dis 2004; 57(5): S1-2.
3. Loria V, Dato I, Graziani F, Biasucci LM. Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes. Mediat Inflamm 2008; 2008: 135625.
4. Nicholls SJ, Hazen SL. The role of myeloperoxidase in the pathogenesis of coronary artery disease. Jpn J Infect Dis 2004; 57(5): S21-2.
5. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005; 25(6): 1102-11.
6. Nambi V. The use of myeloperoxidase as a risk marker for atherosclerosis. Curr Atheroscler Rep 2005; 7(2): 127-31.
7. Podrez EA, Schmitt D, Hoff HF, Hazen SL. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest 1999; 103(11): 1547-60
8. van Paassen P, Cohen Tervaert JW, Heeringa P. Mechanisms of vasculitis: how pauci-immune is ANCA-associated renal vasculitis? Nephron 2007; 105(1): e10-6.
9. Nolan SL, Kalia N, Nash GB, Kamel D, Heeringa P, Savage CO.Mechanisms of ANCA-mediated leukocyte-endothelial cell interactions in vivo. J Am Soc Nephrol 2008; 19(5): 973-84.
10. Jennette JC, Xiao H, Falk RJ. Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol 2006; 17(5): 1235-42.
11. Gibson PG, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001; 119(5): 1329-36.
12. Gelderman MP, Lefkowitz DL, Lefkowitz SS, Bollen A, Moguilevsky N. Exposure of macrophages to an enzymatically inactive macrophage mannose receptor ligand augments killing of Candida albicans. Proceedings of the Society for Experimental Biology and Medicine Society for Experimental Biology and Medicine New York, NY 1998; 217(1): 81-8.
13. Lefkowitz DL, Gelderman MP, Fuhrmann SR, et al. Neutrophilic myeloperoxidase-macrophage interactions perpetuate chronic inflammation associated with experimental arthritis. Clin Immunol 1999; 91(2): 145-55.
14. Gray E, Thomas TL, Betmouni S, Scolding N, Love S. Elevated activity and microglial expression of myeloperoxidase in demyelinated cerebral cortex in multiple sclerosis. Brain Pathol 2008; 18(1): 86-95.
15. Gray E, Thomas TL, Betmouni S, Scolding N, Love S. Elevated myeloperoxidase activity in white matter in multiple sclerosis. Neurosci Lett 2008; 444(2): 195-8.
16. Choi DK, Pennathur S, Perier C, et al. Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J Neurosci 2005; 25(28): 6594-600.
17. Maki RA, Tyurin VA, Lyon RC, et al. Aberrant expression of myeloperoxidase in astrocytes promotes phospholipid oxidation and memory deficits in a mouse model of Alzheimer's disease. J Biol Chem 2009; 284(5): 3158-69.
18. Green PS, Mendez AJ, Jacob JS, et al. Neuronal expression of myeloperoxidase is increased in Alzheimer's disease. J Neurochem 2004; 90(3): 724-33.
19. Lefkowitz DL, Roberts E, Grattendick K, et al. The endothelium and cytokine secretion: the role of peroxidases as immunoregu- lators. Cell Immunol 2000; 202(1): 23-30.
20. Lefkowitz DL, Lefkowitz SS. Macrophage-neutrophil interaction: a paradigm for chronic inflammation revisited. Immunol Cell Biol 2001; 79(5): 502-6.
21. Grattendick K, Stuart R, Roberts E, et al. Alveolar macrophage activation by myeloperoxidase: a model for exacerbation of lung inflammation. Am J Respir Cell Mol Biol 2002; 26(6): 716-22.
22. Suzuki K, Ota H, Sasagawa S, Sakatani T, Fujikura T. Assay method for myeloperoxidase in human polymorphonuclear leukocytes. Anal Biochem 1983; 132(2): 345-52.
23. Pryzwansky KB, MacRae EK, Spitznagel JK, Cooney MH. Early degranulation of human neutrophils: immunocytochemical studies of surface and intracellular phagocytic events. Cell 1979; 18(4): 1025-33.
24. Bradley PP, Christensen RD, Rothstein G. Cellular and extracellular myeloperoxidase in pyogenic inflammation. Blood 1982; 60(3): 618-22.
25. Stahl PD, Ezekowitz RA. The mannose receptor is a pattern recognition receptor involved in host defense. Curr Opin Immunol 1998; 10(1): 50-5.
26. Regnier-Vigouroux A. The mannose receptor in the brain. Int Rev Cytol 2003; 226: 321-42.
27. Allavena P, Chieppa M, Monti P, Piemonti L. From pattern recognition receptor to regulator of homeostasis: the double-faced macrophage mannose receptor. Crit Rev Immunol 2004; 24(3): 179-92.
28. Edwards SW, Nurcombe HL, Hart CA. Oxidative inactivation of myeloperoxidase released from human neutrophils. Biochem J 1987; 245(3): 925-8.
29. Savill JS, Wyllie AH, Henson JE, Walport MJ, Henson PM, Haslett C. Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest 1989; 83(3): 865-75.
30. Aratani Y, Kura F, Watanabe H, et al. In vivo role of myeloperoxi- dase for the host defense. Jpn J Inf Dis 2004; 57(5): S15.
31. Perry VH. The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav Immun 2004; 18(5): 407-13.
32. Lincoln JA, Lefkowitz DL, Cain T, et al. Exogenous myeloper- oxidase enhances bacterial phagocytosis and intracellular killing by macrophages. Inf Immun 1995; 63(8): 3042-7.
33. Lefkowitz DL, Grattendick K, Lefkowitz SS. Myeloperoxidase induction of dendritic cell-derived pro-inflammatory cytokines: disease implications. UK: Dendritic Spines, Nóva Publishers (in press).
34. th ed. (pp. 699-757. Little Brown, NY 1995.
35. Otterness IG. The value of C-reactive protein measurement in rheumatoid arthritis. Semin Arthritis Rheum 1994; 24(2): 91-104.
36. Burmester GR, Stuhlmuller B, Keyszer G, Kinne RW. Mono- nuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis? Arthritis Rheum 1997; 40(1): 5-18.
37. Brennan FM, Maini RN, Feldmann M. TNF alpha-a pivotal role in rheumatoid arthritis? Br J Rheumatol 1992; 31(5): 293-8
38. Fox DA. Cytokine blockade as a new strategy to treat rheumatoid arthritis: inhibition of tumor necrosis factor. Arch Intern Med 2000; 160(4): 437-44.
39. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Ann Rev Immunol 1996; 14: 397-440.
40. Panayi GS. Targeting of cells involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford, England) 1999; 38(Suppl 2): 8-10.
41. Thomas R, MacDonald KP, Pettit AR, Cavanagh LL, Padmanabha J, Zehntner S. Dendritic cells and the pathogenesis of rheumatoid arthritis. J Leukocyte Biol1999; 66(2): 286-92.
42. Cutolo M, Sulli A, Barone A, Seriolo B, Accardo S. Macrophages, synovial tissue and rheumatoid arthritis. Clin Exp Rheumatol 1993; 11(3): 331-9.
43. Edwards SW, Hughes V, Barlow J, Bucknall R. Immunological detection of myeloperoxidase in synovial fluid from patients with rheumatoid arthritis. Biochem J 1988; 250(1): 81-5.
44. Davies EV, Williams BD, Campbell AK. Synovial fluid polymorphonuclear leucocytes from patients with rheumatoid arthritis have reduced MPO and NADPH-oxidase activity. Br J Rheumatol 1990; 29(6): 415-21.
45. van Lent PL, van den Bersselaar L, Grutters GJ, van den Berg WB. Fate of antigen after intravenous and intraarticular injection into mice. Role of molecular weight and charge. J Rheumatol 1989; 16(10): 1295-303.
46. Astern JM, Pendergraft WF 3rd, Falk RJ, et al. Myeloperoxidase interacts with endothelial cell-surface cytokeratin 1 and modulates bradykinin production by the plasma Kallikrein-Kinin system. Am J Pathol 2007; 171(1): 349-60.
47. van Leeuwen MA, Westra J, Limburg PC, van Riel PL, van Rijswijk MH. Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid synovial fluid. Ann Rheum Dis 1995; 54(1): 33-8.
48. Gasson JC. Molecular physiology of granulocyte-macrophage colony-stimulating factor. Blood 1991; 77(6): 1131-45.
49. Lefkowitz DL, Mills KC, Moguilevsky N, Bollen A, Vaz A, Lefkowitz SS. Regulation of macrophage function by human recombinant myeloperoxidase. Immunol Lett 1993; 36(1): 43-9.
50. Sedgwick JD, Riminton DS, Cyster JG, Korner H. Tumor necrosis factor: a master-regulator of leukocyte movement. Immunol Today 2000; 21(3): 110-3.
51. Lefkowitz DL, Mills K, Morgan D, Lefkowitz SS. Macrophage activation and immunomodulation by myeloperoxidase. Proc Soc Exp Biol Med 1992; 199(2): 204-10.
52. Lefkowitz SS, Gelderman MP, Lefkowitz DL, Moguilevsky N, Bollen A. Phagocytosis and intracellular killing of Candida albicans by macrophages exposed to myeloperoxidase. J Infect Dis 1996; 173(5): 1202-7.e (New York, NY 1992; 199(2): 204-10.
53. Lemanske RF, Jr., Busse WW. Asthma. JAMA 1997; 278(22): 1855-73.
54. Ward PA. Phagocytes and the lung. Ann NY Acad Sci 1997; 832: 304-10.
55. Virani SS, Polsani VR, Nambi V. Novel markers of inflammation in atherosclerosis. Curr Atheroscler Rep 2008; 10(2): 164-70.
56. Vita JA, Brennan ML, Gokce N, et al. Serum myeloperoxidase evels independently predict endothelial dysfunction in humans. Circulation 2004; 110(9): 1134-9.
57. Levinson SS. Inflammatory and long-term risk markers. Clin Lab Med 2006; 26(3): 553-70.
58. Pattison DI, Davies MJ. Reactions of myeloperoxidase-derived oxidants with biological substrates: gaining chemical insight into human inflammatory diseases. Curr Med Chem 2006; 13(27): 3271-90.
59. Davies MJ, Hawkins CL, Pattison DI, Rees MD. Mammalian heme peroxidases: from molecular mechanisms to health implications. Antioxid Redox Signal 2008; 10(7): 1199-234.
60. Bonomini F, Tengattini S, Fabiano A, Bianchi R, Rezzani R. Atherosclerosis and oxidative stress. Histol Histopathol 2008; 23(3): 381-90.
61. Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr Opin Cardiol 2006; 21(4): 322-8.
62. Arimura Y, Minoshima S, Kamiya Y, et al. Serum myeloperoxidase and serum cytokines in anti-myeloperoxidase antibody-associated glomerulonephritis. Clin Nephrol1993; 40(5): 256-64.
63. Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003; 108(12): 1440-5.
64. Brennan FM, Maini RN, Feldmann M. TNF alpha--a pivotal role in rheumatoid arthritis? Br J Rheumatol1992; 31(5): 293-8.
65. Huugen D, Cohen Tervaert JW, Heeringa P. TNF-alpha bioactivity-inhibiting therapy in ANCA-associated vasculitis: clinical and experimental considerations. Clin J Am Soc Nephrol 2006; 1(5): 1100-7.
66. Hsieh SC, Yu HS, Cheng SH, et al. Anti-myeloperoxidase antibodies enhance phagocytosis, IL-8 production, and glucose uptake of polymorphonuclear neutrophils rather than anti- proteinase 3 antibodies leading to activation-induced cell death of the neutrophils. Clin Rheumatol 2007; 26(2): 216-24.
67. Kallenberg CG. Pathogenesis of PR3-ANCA associated vasculitis. J Autoimmune 008; 30(1-2): 29-36.
68. Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet 2006; 368(9533): 404-18.
69. Jayne D. The clinical features and pathology of vasculitis associated with anti-myeloperoxidase autoantibodies. Jpn Inf Dis 2004; 57(5): 16-7.
70. Williams J, Hewins P, Savage C. The influence of autoantibodies to myeloperoxidase on neutrophil function and intracellular signaling. Jpn Inf Dis 2004; 57(5): S5-6.
71. Nagatsu T, Sawada M. Inflammatory process in Parkinson's disease: role for cytokines. Cur Pharm Design 2005; 11(8): 999- 1016.
72. Reynolds WF, Rhees J, Maciejewski D, et al. Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Exp Neurol 1999; 155(1): 31-41.
73. Akama KT, Van Eldik LJ. Beta-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1beta- and tumor necrosis factor-alpha (TNFalpha)-dependent, and involves a TNFalpha receptor-associated factor- and NFkappaB-inducing kinase-dependent signaling mechanism. Biol Chem 2000; 275(11):7918-24.
74. Hendriks JJ, Teunissen CE, de Vries HE, Dijkstra CD. Macrophages and neurodegeneration. Brain Res 2005; 48(2): 185- 95.
75. Weisman D, Hakimian E, Ho GJ. Interleukins, inflammation, and mechanisms of Alzheimer's disease. Vitam Horm 2006; 74: 505- 30.
76. Sawada M, Imamura K, Nagatsu T. Role of cytokines in inflammatory process in Parkinson's disease. J Neural Transm 2006; (70): 373-81.
77. Simard AR, Rivest S. Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer's disease. Mol Psychiatr 2006; 11(4): 327-35.
78. Glezer I, Simard AR, Rivest S. Neuroprotective role of the innate immune system by microglia. Neuroscience 2007; 147(4): 867-83.
79. Rogers J, Lue LF. Microglial chemotaxis, activation, and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer's disease. Neurochem Int 2001; 39(5-6): 333-40.
80. Yap YW, Whiteman M, Cheung NS. Chlorinative stress: an under appreciated mediator of neurodegeneration? Cell Signal 2007; 19(2): 219-28.
81. Lefkowitz DL, Lefkowitz SS. Microglia and myeloperoxidase: a deadly partnership in neurodegenerative disease. Free Radic Biol Med 2008; 45(5): 726-31.